Safety
Also known as: Accident prevention
Methodology & AI Transparency ⓘ
Safety Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: You can't remove all the safety hazards from your life, but you can reduce them.
- 2 Real-world patient consensus: Mapped to Men's Health, Testosterone & Sexual Function under ICD-10-CM E29.6 for Safety clinical workups.
- 3 Typical cash cost range: Primary evaluation for Safety incorporates cardiometabolic workup [Safety E29.6] and symptom diary review.
- 4 Top reported side effects / signs: Key Men's Health & TRT biomarkers for Safety (E29.6): Hematocrit & Total in Safety (E29.6: PSA) & Ultrasensitive Estradiol & in Safety (E29.6: ApoB) (E2 20–38 pg/mL; ApoB < 80 mg/dL (E29.6)).
Ask our AI Specialists anything about Safety
What Is Safety?
You can't remove all the safety hazards from your life, but you can reduce them. To avoid many major hazards and prepare for emergencies: Keep emergency phone numbers by your telephones Make a first aid kit for your home Make a family emergency plan Install and maintain smoke alarms and carbon monoxide detectors Keep guns unloaded and locked up. Lock up the ammunition separately. Follow the directions carefully when using tools or equipment Young children are especially at risk. Supervision is the best way to keep them safe. Childproofing the house can also help.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Safety (E29.6, Men's Health & TRT) reflects primary testicular Leydig in Safety (E29.6: cell insufficiency or). Cross-referenced with NIH MeSH (Safety), longitudinal control is benchmarked via Hematocrit & Total in Safety (E29.6: PSA).
Common Symptoms & Clinical Signs
- • Keep emergency phone numbers by your telephones
- • Make a first aid kit for your home
- • Presentation of Safety (E29.6): loss of lean in Safety (E29.6: muscle recovery, rising)
- • Secondary Safety clinical sign: blunted motivation, depressed in Safety (E29.6: mood, or declining)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Safety Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E29.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Men's Health, Testosterone & Sexual Function | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Hematocrit & Total in Safety (E29.6: PSA) | Hct < 50%; age-appropriate PSA (E29.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ultrasensitive Estradiol & in Safety (E29.6: ApoB) | E2 20–38 pg/mL; ApoB < 80 mg/dL (E29.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Morning Total & in Safety (E29.6: Free Testosterone (2x) | Total 500–900 ng/dL; Free 110–210 pg/mL (E29.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Safety
Treatment selection for Safety depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Safety)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of empagliflozin as add-on to metformin for type 2: What a 4,256-Participant Study Found EMPA as add-on to MET was well tolerated and provided additional benefits beyond glucose lowering, such as weight loss and blood pressure reduction. European journal of clinical pharmacology • 2016-06-15 • Meta-Analysis | N = 4,256 | 99/100 | PMID 26832915 ↗ |
| New Insights on Real-world benefits and safety of liraglutide in the obese, non-diabetic: What a 4,754-Participant Study Found This systematic review and meta-analysis indicates that liraglutide to be an effective and safe treatment for weight loss in the obese, non-diabetic individuals. African health sciences • 2019-09-15 • Meta-Analysis | N = 4,754 | 99/100 | PMID 32127832 ↗ |
| New Insights on Benefits and safety of 11 sodium-glucose cotransporter-2 inhibitors at different: What a 9,144-Participant Study Found As add-on therapy, SGLT2is demonstrated favourable antidiabetic efficacy and acceptable safety. BMJ open • 2025-02-26 • Meta-Analysis | N = 9,144 | 99/100 | PMID 40010842 ↗ |
| New Insights on Comparative real-world benefits and safety of 8 GLP-1RAs in patients with type 2: What a 11,126-Participant Study Found Overall GLP-1RAs were more efficacious than placebo in patients with T2D on efficacy. Diabetes research and clinical practice • 2021-07-15 • Meta-Analysis | N = 11,126 | 99/100 | PMID 34102249 ↗ |
| New Insights on Potent incretin-based therapy for: What a 5,140-Participant Study Found The side effects related to semaglutide and tirzepatide were primarily of mild-to-moderate severity and mostly gastrointestinal, which was more frequent during the dose-titration period and leveled off during the treatment period. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2024-05-15 • Meta-Analysis | N = 5,140 | 99/100 | PMID 38463003 ↗ |
Safety Patient Community & “People Like Me” Threads
Filter Safety community threads and patient logs by age, biological sex, dosage, and treatment duration.